Physician profile
Cornelia E Crum
NPI 1063093151
$3,098.21
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,646 · 2022: $1,453.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $585.51 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $515.05 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $477.15 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $347.19 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $248.88 | 2021-2022 | |
| Alkermes, INC. | $244.67 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $218.03 | 2021-2022 | |
| Abbvie INC. | $168.80 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $113.01 | 2021-2022 | |
| Indivior INC. | $84.57 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.72 | 2021 | |
| Noven Therapeutics, LLC | $23.58 | 2021 | |
| Eisai INC. | $16.40 | 2021 | |
| Lundbeck LLC | $15.28 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.37 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornelia Crum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.